We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
- Authors
Elamin, Yasir Y.; Gomez, Daniel R.; Antonoff, Mara B.; Robichaux, Jacqulyne P.; Tran, Hai; Shorter, Melissa K.; Bohac, Jadi M.; Negrao, Marcelo Vailati; Le, Xiuning; Rinsurogkawong, Waree; Lewis, Jeff; Lacerda, Lara; Roarty, Emily B.; Swisher, Stephen G.; Roth, Jack A.; Zhang, Jianjun; Papadimitrakopoulou, Vassiliki; Heymach, John V.
- Abstract
<bold>Introduction: </bold>Although most NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutations have an impressive initial response, the vast majority has residual disease and develops acquired resistance after 9 to 14 months of EGFR tyrosine kinase (TKI) therapy. We recently reported a phase II trial showing that, for patients with molecularly unselected oligometastatic NSCLC who did not progress after first-line systemic therapy, local consolidation therapy (LCT) with surgery or radiation improved progression-free survival (PFS), compared with maintenance therapy alone. Herein, we report a retrospective analysis of LCT after TKI in patients with metastatic EGFR mutant NSCLC.<bold>Patients and Methods: </bold>We identified patients with metastatic EGFR mutant NSCLC treated with TKI plus LCT or with TKI alone in the MD Anderson GEMINI (Genomic Marker-Guided Therapy Initiative) database and in our recently published LCT trial. PFS was compared between LCT plus TKI and TKI only treated patients using the log-rank test.<bold>Results: </bold>We identified 129 patients with EGFR mutant NSCLC who were treated with first-line TKI and 12 that were treated with TKI followed by LCT. Among the 12 patients treated with TKI plus LCT, 8 patients had oligometastatic disease (defined as ≤ 3 metastases), and 4 patients had > 3 metastases. LCT regimens were hypofractionated radiotherapy or stereotactic ablative body radiotherapy for 11 patients and surgery for 1 patient. TKI followed by LCT resulted in a significantly longer PFS (36 months) compared with TKI alone (PFS, 14 months; log-rank P = .0024).<bold>Conclusions: </bold>Our data suggests that first-line TKI plus LCT is a promising therapeutic strategy for patients with EGFR mutant NSCLC that merits further investigation.
- Publication
Clinical Lung Cancer, 2019, Vol 20, Issue 1, p43
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2018.09.015